Orilissa is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Elagolix Sodium.
Product ID | 0074-0039_10c7c8a9-573a-02a3-97b4-50f953145beb |
NDC | 0074-0039 |
Product Type | Human Prescription Drug |
Proprietary Name | Orilissa |
Generic Name | Elagolix |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2018-07-23 |
Marketing Category | NDA / NDA |
Application Number | NDA210450 |
Labeler Name | AbbVie Inc. |
Substance Name | ELAGOLIX SODIUM |
Active Ingredient Strength | 200 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2018-07-23 |
NDC Exclude Flag | N |
Sample Package? | Y |
Marketing Category | NDA |
Application Number | NDA210450 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-07-23 |
Marketing Category | NDA |
Application Number | NDA210450 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2018-07-23 |
Marketing Category | NDA |
Application Number | NDA210450 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-07-23 |
Ingredient | Strength |
---|---|
ELAGOLIX SODIUM | 200 mg/1 |
SPL SET ID: | a86757b3-09c5-fd3b-1223-244e94f50a66 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0074-0038 | Orilissa | Elagolix |
0074-0039 | Orilissa | Elagolix |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ORILISSA 87104202 5617902 Live/Registered |
AbbVie Inc. 2016-07-14 |